| Date Filed | Type | Description |
| 08/17/2023 |
4
| Douglas Earl Martin (GENERAL COUNSEL) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 108,958 shares
@ $0
Granted 326,876 shares
@ $0
Granted 960,854 options to buy
@ $4.13, valued at
$4M
|
|
| 08/17/2023 |
3
| Douglas Earl Martin (GENERAL COUNSEL) has filed a Form 3 on Allogene Therapeutics, Inc. |
| 08/14/2023 |
4
| CHEN YINLIN JACK (SVP, Finance) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 11,401 shares
@ $0
Granted 39,160 options to buy
@ $4.21, valued at
$164.9k
|
|
| 08/14/2023 |
3
| CHEN YINLIN JACK (SVP, Finance) has filed a Form 3 on Allogene Therapeutics, Inc. |
| 08/09/2023 |
4
| Mayo Stephen (Director) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Sold 10,000 shares
@ $4.2855, valued at
$42.9k
|
|
| 08/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
SC 13G
| FMR LLC reports a 17.1% stake in ALLOGENE THERAPEUTICS INC |
| 06/29/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/15/2023 |
4
| MESSEMER DEBORAH M. (Director) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 74,561 shares
@ $0 |
|
| 06/15/2023 |
4
| Barrett Elizabeth A. (Director) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 116,120 options to buy
@ $5.7, valued at
$661.9k
|
|
| 06/15/2023 |
4
| SATO VICKI L (Director) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 59,649 shares
@ $0
Granted 23,224 options to buy
@ $5.7, valued at
$132.4k
|
|
| 06/15/2023 |
4
| Humer Franz B (Director) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 74,561 shares
@ $0 |
|
| 06/15/2023 |
4
| WITTE OWEN N. (Director) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 74,561 shares
@ $0 |
|
| 06/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/07/2023 |
8-K
| Other Events Interactive Data |
| 04/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/26/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/24/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/24/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
4
| Smith Lillian (VP, Corporate Counsel) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 56,545 shares
@ $0 |
|
| 04/05/2023 |
3
| Smith Lillian (VP, Corporate Counsel) has filed a Form 3 on Allogene Therapeutics, Inc. |
| 03/24/2023 |
4
| MOORE ALISON (Chief Technical Officer) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 558,094 shares
@ $0
Granted 432,738 options to buy
@ $5.04, valued at
$2.2M
|
|
| 03/24/2023 |
4
| SCHMIDT ERIC THOMAS (CFO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 558,094 shares
@ $0
Granted 432,738 options to buy
@ $5.04, valued at
$2.2M
|
|
| 03/24/2023 |
4
| Roberts Zachary (EVP of R&D) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 148,035 shares
@ $0 |
|
| 03/24/2023 |
4
| Belldegrun Arie (Director) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 1,282,976 shares
@ $0
Granted 994,800 options to buy
@ $5.04, valued at
$5M
|
|
| 03/24/2023 |
4
| Chang David D (President and CEO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 1,924,464 shares
@ $0
Granted 1,492,200 options to buy
@ $5.04, valued at
$7.5M
|
|
| 03/16/2023 |
4
| Chang David D (President and CEO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 22,340 shares
@ $5.56, valued at
$124.2k
|
|
| 03/16/2023 |
4
| SCHMIDT ERIC THOMAS (CFO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 35,879 shares
@ $5.47, valued at
$196.3k
|
|
| 03/16/2023 |
4
| MOORE ALISON (Chief Technical Officer) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 8,351 shares
@ $5.5071, valued at
$46k
|
|
| 03/16/2023 |
4
| Bhavnagri Veer (General Counsel) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 23,628 shares
@ $5.67, valued at
$134k
|
|
|